Teldar Paper retweeted
$ABVX Scorpion called Abivax a fraud. To believe that requires the reader to completely dismiss the very large clinical dataset and/or believe this is the greatest conspiracy in the history of medicine by an order of magnitude. Show the falsified records. Show the cancer excess at the dose you’re attacking. Explain why blinded readers saw healthier colons on both scopes and biopsies. The evidence Scorpion made public falls well short of its headline, and they themselves tell you that they've already covered their short position by the time you read through the report. scorpioncapital.com/
Start with 50 mg dose.
In June, we estimated 0.59 cancers per 100 patient-years at 50 mg, excluding non-melanoma skin cancer. We kept the doses separate because 50 mg was the dose under scrutiny. Abivax’s July deck put the updated number at 0.64 across 944 patient-years at 50 mg, within its historical ulcerative colitis range of 0.30–0.70. Non-melanoma skin cancer also came in at 0.64, below the company’s 0.70–1.40 benchmark. Those are the 50 mg numbers. teapaw.org/deathtouch2k/status/20… · ir.abivax.com/static-files/b…
Yes, the narrower Phase 3 maintenance analysis came in higher. Four cases over 438 patient-years gave you 0.91. The added Part 2 data had two cases over 288 patient-years, or 0.69. One patient had a platelet count over 900,000 at baseline and was later diagnosed with a blood-cell cancer. The other was diagnosed with prostate cancer after roughly three months on the drug. Investigators assessed both as unrelated. Then you get to the full 50 mg dataset and the rate is 0.64. If your case depends on the smaller slice, explain why the rest of the exposure should count for less rather than ignoring it because it's inconvenient to your short report credibility. sec.gov/Archives/edgar/data/…
Scorpion’s UVA experiment is a lab measurement of light absorption. The public trial protocol already disclosed animal phototoxicity for obefazimod’s main breakdown product and required sun precautions and skin monitoring. The observed 50 mg skin cancer rate across Phase 2 and 3 still came in below the historical benchmark. That comparison leaves room for a rare or delayed risk, but again no evidence. It makes the sweeping cancer claim a lot harder to sell AND physicians are already screening for skin cancer risk due to OTHER STANDARD OF CARE DRUGS THAT CAUSE CANCER IN THESE PATIENTS AND CAN CONFOUND THE SKIN CANCER FINDINGS IN EXPERIMENTAL DRUG TRIALS. scorpionreports.s3.us-east-2… · cdn.clinicaltrials.gov/large… · ir.abivax.com/static-files/b…
Now explain the biopsies.
Two blinded Phase 3 trials randomized 1,275 patients. At 50 mg, eight-week remission was 21.7% vs 2.5% on placebo in one trial and 19.8% vs 6.3% in the other. The 25 mg dose missed the main endpoint in the second trial. The 50 mg dose hit it in both. sec.gov/Archives/edgar/data/…
Then 580 patients who had responded to obefazimod were randomized again. After 44 more weeks, 51% were in remission on either dose versus 10% after switching to placebo. A normal-looking colon on scope? 42% at 25 mg, 48% at 50 mg, 10% on placebo. Improvement confirmed by both scope and biopsy? 50%, 57%, 10%. If widespread gut-cell damage is your explanation for how this drug works, explain why the tissue looked healthier under the microscope. abivax.com/wp-content/upload…
And the evidence goes back further. All three doses improved the main disease-activity score in the 254-patient Phase 2b trial. In the open-label follow-up, 114 of 217 were in remission at two years, with missing results counted as failures. In a separate, selected group that stepped down to 25 mg, 88 of 130 were in remission three years later. That’s a substantial record of follow-up on top of the three blinded Phase 3 trials. sciencedirect.com/science/ar… · academic.oup.com/ecco-jcc/ar… · sec.gov/Archives/edgar/data/…
“Foreign trials” is doing a lot of work here.
The Phase 3 trials enrolled across 36 countries. Eastern Europe accounted for 38% of enrollment. In Western Europe, 50 mg remission was 19.0% vs 5.6% on placebo. In a smaller exploratory North American group, it was 8 of 62 vs 0 of 36, with scopes also favoring treatment. The protocol called for independent central readers who were blinded to treatment and visit order. If Scorpion has evidence of misconduct, show the sites, the records and what happens to the results when those sites are removed. sec.gov/Archives/edgar/data/… · academic.oup.com/ecco-jcc/ar… · abivax.com/wp-content/upload… · cdn.clinicaltrials.gov/large…
The “150-fold” experiment used zero cells. ZERO CELLS. Why are we relying on experiments that don't even include living cells when we have thousands of patient years worth of safety data?
Scorpion measured about one-fifth of the nominal drug concentration in a cell-free reconstruction, then applied that result to cell data from 2015 to get the 150-fold headline. That raises a question about an old assay. The DDT comparison is based on fat solubility. In people given 50 mg, the parent drug’s plasma half-life was about one hour and its main breakdown product’s was about four days. If the claim is dangerous accumulation in human tissue, show the tissue exposure. scorpionreports.s3.us-east-2… · scorpionreports.s3.us-east-2… · journals.asm.org/doi/10.1128…
And the supposedly fictitious biology was measured in patients. Both doses raised miR-124 in blood and colon tissue versus placebo in Phase 3, following the same finding in Phase 2. The Phase 3 analysis included 673 paired sigmoid biopsies, alongside paired rectal biopsies and blood samples. Scorpion can question the old binding assay. It still has to deal with the separate structural work and the biological change measured in actual patients. scorpionreports.s3.us-east-2… · academic.oup.com/ecco-jcc/ar… · pmc.ncbi.nlm.nih.gov/article… · abivax.com/wp-content/upload…
The cancer cases deserved a serious look in June. We did the math then, and the expanded 50 mg data landed right within our estimates of background cancer rates in ulcerative colitis patients. Scorpion has a set of lab hypotheses and a fraud headline and completely ignores the fact the drug has show ZERO EVIDENCE OF ANYTHING THEY CLAIM IN THOUSANDS OF HUMAN BEINGS AND THEREFORE IS MOST LIKELY COMPLETELY WRONG.
Abivax has two positive 50 mg induction trials, a positive randomized maintenance trial at both doses, and biopsies that show the colon getting healthier. If you want to overturn that record, bring CLINICAL EVIDENCE that can explain it.
$ABVX As a follow-up to a few posts that I saw regarding the perceived elevated rates of NMSC and malignancies in the 50 mg arm specifically in the phase 3:
A few thoughts:
1) The phase 3 50 mg dose is actually a small minority of the patient years of safety data acquired -- the much larger dataset for that dose comes from the phase 2b long-term open label follow-up, which can be reasonably pooled with the phase 3 results given the same dose and detection protocols (Note, we have seen some analyses that pool 25 mg and 50 mg arms. We would NOT recommend doing this as it is not fair to claim that the risk of developing cancer in the 25 mg arm is known to be the same as the 50 mg arm). Pooling 50 mg phase 2b and 50 mg phase 3 data sets yields a much lower rate of events across the board. (I suspect it was just a bit of bad luck on the smaller phase 3 dataset for the 50 mg dose in isolation, see below chart for what we've been working off of after integrating these phase 2 data -- note there are some assumptions that go into this but the variability should be pretty de minimis);
2) Two ways things generally cause cancer: DNA damage from some oxidative/radiation/something else source that damages DNA or inhibits DNA repair mechanisms at their core OR substantial or highly targeted immunosuppression. Because both of these events are total exposure related, typically events accelerate over time. The phase 2 had the much longer follow-up with fewer patients whereas the phase 3 had more patients followed up for less time. The phase 2 had a very low number of events, and the phase 3 50mg dose was the only arm that had an elevated set. A priori, if the drug was a carcinogen, we would have expected the opposite: that the phase 2 would have a higher incidence/100 PY than the phase 3 given the individual patient exposures on a cumulative basis to such carcinogens are much higher in the phase 2 than the phase 3 in addition to the idea that there is a delay between when the carcinogen can cause the malignancy to when it can be detected (and T=0 is always the first instance in which that timer could start). Also, if the drug was as immunosuppressive as would be needed to cause cancer, you would expect to see a boatload of opportunistic infection before you'd see the cancer signal -- we see none.;
3) Pre-clinical testing confirmed that the drug is actually an anti-proliferative -- we would have expected the drug to be protective against tumor growth, not stimulating it;
4) No consistency or clustering for any cancer type at any time point;
5) NMSC carries a much different (lower) risk profile than other types of malignancies since they are caught very easily and have a low rate of metastases, and are seen at a massively disproportionately high case numbers relative to other types of malignancies (also included in the bottom table following pooling of the 50 mg arm), so FDA is less concerned about it than non-NMSC;
6) To warrant a black box, the FDA usually requires, at a minimum, consistency of preclinical and/or striking clinical datapoints such that careful consideration must be made to determine if the benefit/risk profile inverts in a subset of all patients that may receive the drug. In this case, we not only have completely disparate and conflicting datapoints, but we even have one data point relating to the MoA and pre-clinical data findings that suggest the drug should have the opposite effect. In addition, black box decisions are not made in isolation. They are heavily debated back and forth between the company, internally, require a lot of internal consensus on establishing causal link, and are not made in a vacuum to unmet need and efficacy;
7) UC patients have an elevated rate of inflammation (by definition) and, in turn, elevated rates of cancer compared to healthy individuals (~+.5 events/100PY vs non-UC). Obefazimod is now a proven highly effective therapy that leads to robust endoscopic remissions and attenuation of much of this inflammatory effect. I would hypothesize if you ran a large enough study and followed patients for long enough, you would find that there would be a cancer benefit from the drug secondary to the disease control that it would afford. The weight of this potential benefit (which makes sense given the pathophysiology) must be considered against the risk of the agent itself causing cancer (for which we have no reason to believe it actually should cause cancer).
Teldar Paper retweeted
$AMZN owns more Anthropic shares than all Anthropic's founders combined
Teldar Paper retweeted
$CGON quick thoughts before I catch a flight. New PT $150
HR 0.32!!!! Clean safety
LG was 3/4 events so HG alone could never drag the pooled HR anywhere near here. A 0.32 means it works in LG too.
$cgon now is:
• Only adjuvant drug for ~50K US IR pts with no approved option
• BLA for IR + HG Ta in 2Q27, plus a broader BCG unresponsive filing
• Backbone across NMIBC!
Why $150: at 0.32 creto is SOC in IR. at 0.32 and $4bn+ peak is reasonable. 3x peak sales plus ~$1bn cash is ~$150, before any M&A premium.
And it's now one of the cleanest strategic assets in onc. Own manufacturing, ANI royalty fight won, no converts, randomised IR data nobody else has.
$KOD went 50 to 80 on the day and kept going. Same setup.
Teldar Paper retweeted
$MDGL Analysts question whistleblower allegations against Madrigal
Teldar Paper retweeted
$KURA The most undervalued commercial onco-play?
Late 2025 approved AML drug ziftomenib is rapidly gaining traction: Q2 sales $9.1M (+57% QoQ), and they already have the majority of new starts in r/r NPM1m AML (per Kura). IMO, investors have underestimated the once-daily dosing vs $SNDX twice-daily + potential cardiac safety edge.
The biggest upside is still frontline AML: $350-400M current US TAM vs $7B expanded TAM. Mgmt sees $3B peak sales potential. ASH (abstracts Nov 4): possible aza/ven durability, FLT3 combos & broader AML data. Earlier 96% CRc with ziftomenib + 7+3. Durability will be a key, a lot to expect for esp. updated data at ASH in dec.
Risks: J&J bleximenib (Ph3, update schedule not given) & $SNDX competition.
A great commercial play with significant upsise, and if the frontline data holds up, we are looking at 3x-10x the valuation. CEO just having bought shares twice and talked about adding also reassures the long term theses.
Next catalyst: earnings and ASH abstracts both in two weeks.
Do your own DD.
Teldar Paper retweeted
$TGTX Prakhar - Positioning seems long into earnings, as investors noted to us that third-party data sources, such as claims data, suggest a strong Q3
Teldar Paper retweeted
$LQDA $xbi
Good news, and a victory for reasonableness.
A good outcome all around, and especially for patients — global settlement:
> Fully resolves all six ongoing lawsuits between the companies
> Maintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH)
> Liquidia (LQDA) to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation against United Therapeutics
> Strong financial position with $222.7 million in Q3’26 YUTREPIA net product sales (preliminary, unaudited), contributing to $396.1 million in cash and cash equivalents as of September 30, 2026
> Liquidia will continue to advance YUTREPIA and L606 clinical programs as previously outlined
Teldar Paper retweeted
In 15 months $nktr has gone from
$8 to $37
$37 to $21
$21 to $65
$65 to $33
$33 to $73
$73 to $62
$62 to $109
$109 to $54
$54 to $77
$77 to $43
This latest move is “not different this time”.
Teldar Paper retweeted
$CGEM initiates NDA submission for Zipalertinib in NSCLC under FDA’s Real-Time Oncology Review (RTOR) program
Teldar Paper retweeted
Sometimes the ugliest headlines make for the most interesting entry points.
Case in point: $LQDA — Liquidia.
The stock closed at $30.26 after falling 57% yesterday and is now around $25.32 pre-market.
I spent this morning going through the decision, the numbers, some of the relevant patent case law, and the new sell-side work.
My conclusion: the headline looks considerably worse than the range of plausible economic outcomes.
Here’s how I’m thinking about it 🧵👇
Teldar Paper retweeted
I find the Judge's reasoning on Claim 1 & Claim 14 very weird wrt $LQDA . Why would he say he was considering a motion to strike based on Rule 37 and probe the backdating and then do this?
In his opinion he says LQDA had adequate notice because common ownership was mentioned thrice in the pre-trial package and that was adequate disclosure.
Ok, so common ownership was mentioned thrice in 1,400 page pre-trial briefs. Two of those mentions were $UTHR saying they had common ownership, the third mention was them actually promising to produce proof of it.
LQDA submitted an interrogatory asking for said proof a full year even before the pre-trial package. UTHR never responded to that and the three responses the came later as I mention above, once again provide absolutely no proof at all.
For some reason Judge found this disclosure not only adequate but he also then accepted Byrd’s trial testimony as proof.
He resolved by accepting UTHR’s argument that managing Orange Book patents falls within Byrd’s disclosed regulatory responsibilities. He therefore found that LQDA had adequate notice of the subject.
But does familiarity with FDA patent listings necessarily establish knowledge of who owned the underlying inventions on particular historical dates?
All this while UTHR still had disclosure obligations, and Byrd needed a basis for personal knowledge.
I get that the law is blind, but can it blind to such an extent? The tricks played by UTHR in this case have already imo changed the IP litigation landscape.
What's to stop someone from doing the same underhanded things and citing Richard G. Andrews?
Teldar Paper retweeted
Pretty good handicap outcome scenario for $LQDA $UTHR from sharp sell side analyst
Per legal KOL feedback, both parties have 1 week to agree on the injunction.
Our KOL doesn't expect LQDA to push back on this point, as they would likely want a cooperative Judge as they seek a skinny PAH label.
Appeal?
Both companies had said previously that they planned to appeal in a loss scenario.
Our legal KOL believes that LQDA's path to eventually winning requires the same strategy, which is to challenge the '793 patent as admissible prior art. However, the legal KOL thinks Judge Andrews conveyed that the issue of '793 admissibility was clear during the trial which he presided over, and thus he thinks it will be difficult for an appellate court to conclude this was not the case.
What happens next?
High probability - UTHR and LQDA reach agreement on injunction for judge to sign w/in a week, though the financial penalty (e.g., damage compensation, potential royalty) will be calculated later. The injunction should also provide clarity as to whether exiting Yutrepia PH-ILD patients will be allowed to stay on Yutrepia.
Low probability - if they do not agree on an injunction, we understand that the Judge may step in himself and give an injunction regardless.
What are the damages, and could there be a deal? Our KOL expects the economic value of the damages will be rooted in the lost profit to UTHR, of each Yutrepia unit sold for PH-ILD. Thus, if there is a royalty deal, we would expect it to likewise reflect this value. The value of a royalty is that it may be easier logistically, but we would expect this to also contemplate UTHR's lost profit to future PH-ILD through '327's expiry (~2042).
LQDA stock impact - We think LQDA shares could trade to the high $30's near term in this scenario. Per our model, removing future PH-ILD from Yutrepia lowers our Yutrepia value to $24/sh, though we anticipate some credit for L606.UTHR stock impact - We had been anticipating +5-10% in this scenario.
Teldar Paper retweeted
We think that today or tomorrow are potential decision days for Andrews. He had 3 bench trials during this last term that were unresolved as of a week ago. He resolved one of them on Friday. He has still has the $LQDA case and the $WBD case. He has never had a bench trial appear on the CJRA list twice, which both of these would if we extend passed Wednesday.
It seems highly unlikely that he has a third clerk look at the $LQDA case (or the $WBD case), which means that we likely already have an opinion done. Perhaps there are some tweeks left but he has in the past shown that this CJRA deadline is meaningful (see below) with rulings coming slightly before and then the day of.
Let this long wait finally be over.
Teldar Paper retweeted
$ABVX Combination strategy and next-generation pipeline updates expected around JPM
Q1 2027 should be very eventful
RT @seedy19tron: *** $nktr vs $lly breaking
3 more notes passed from jury this morning, feedback from sources on ground was they leaned po…
Teldar Paper retweeted
Wall Street Jumped the Gun: The Big Overread in Nektar v. Lilly
On Tuesday, when the jury asked Judge Donato to clarify the difference between finding a breach with $1 in nominal damages versus finding no breach at all, Wall Street treated a single note as the verdict. Nektar ($NKTR) stock came under pressure on the headline: the Jury is letting Lilly ($LLY) walk.
Treating one note from an 8-person panel as the unanimous voice of the jury is a massive overread - especially in San Francisco.
Wall Street assumed a jury will take the simplest path. A San Francisco jury hasn’t appeared to do that. The Jury pool is drawn from a sophisticated Bay Area demographic with an unusually high understanding of data integrity issues. They understand the difference between a typo and a systemic review failure. The two notes this jury sent show that sophistication.
Tuesday's note at the roughly 13-hour mark confirms the $0-to-$1 outcome is being discussed, but it doesn't dictate direction.
Instructions 13 and 15 create a fork: Instruction 13 says Nektar must prove Lilly failed to use Commercially Reasonable Efforts and that it sustained damages, while Instruction 15 says damages must be reasonably certain. A jury that believes Lilly breached CRE but is divided on whether Nektar proved its full damages with reasonable certainty naturally asks: does that uncertainty force us to flip to no breach?
Donato's answer gave them permission to keep liability intact - breach with nominal is a finding of liability, no breach is not. That clarification is most useful to a panel that is coalescing around breach and is trying to preserve that finding while it works through damages.
The sentence the market ignored
One potential reason the jury may have spent another 10-plus hours after that instead of going home is in Instruction 15 itself:
"It is for you to determine what damages, if any, have been proved... When the existence of damage is certain and the only uncertainty is as to its amount, Nektar may not be denied recovery as long as it shows a stable foundation for a reasonable estimate of damages."
That is the opposite of a $1 trap. It instructs the jury they are forbidden from denying recovery if there is a stable foundation, even if they reject the exact expert number.
The sushi test: why Jury’s other questions matters so much
Late Wednesday, at roughly the 24 hours of deliberations mark, the jury asked (paraphrased): “If a business works with a company that you know is at a higher risk of inaccurate data, is that business' normal data-review efforts reasonable with the known risks?"
Think of it like a sushi restaurant.
You normally trust your fish delivery and do a quick smell test. Then you learn your supplier just had two FDA warnings for spoilage. Is it still "reasonable" to do the same quick smell test? No. A reasonable owner starts opening boxes, checking temps, may even consider switching suppliers. Doing "what you usually do" when you know risk is higher is the definition of unreasonable.
That is exactly what is at issue under CRE. Under the Agreement, Lilly is liable for PRA's acts and omissions, including the miscalculation that reported Rezpeg's efficacy at 66% at EADV 2022 when the corrected data showed 83%. Lilly's defense has been "we did what we normally do for comparable products."
This jury - a Bay Area jury that lives with QA - is asking whether normal is still reasonable when you are on notice that your data source is high-risk.
If they believed standard oversight was sufficient to satisfy CRE, they would have returned a defense verdict. Instead, they are testing whether Lilly's failure to add safeguards when it knew risk was elevated.
Teldar Paper retweeted
$NKTR
Lots of funky action in this name the past few days, some specific to the ongoing court case and some from bio as a whole. Let's unpack it.
The jury note, paraphrased as "Is there a difference between breach + $1 and no breach + $0?", spooked the market and sent the stock down sharply. Two sides to this.
First, the note is informative, but only a little. It tells us at least one juror sees the $0/$1 outcome as part of their possible resolution space. Where I think the market (or at least fintwit) got it wrong is treating the note as the voice of the entire jury. It could reflect the whole panel, or it could be a single juror's question. It doesn't even tell us direction: it could come from a juror looking for a way to find breach despite doubting the damages case. The price action implied the whole jury is now choosing between $0 and $1, which I think is a big overread.
Second, this is NKTR: a retail/fintwit-heavy, relatively illiquid SMID-cap biotech that moves 5% on a random Tuesday with no news. A 10% move on this headline looks extreme, but near-term price action here mostly reflects value-agnostic traders playing local news and liquidity flow, not a considered repricing of long-term value.
The bigger picture: the case is largely a distraction from the real value, which is Rezpeg. I'm not a biotech expert, but the sell side and most biotech specialists I respect see it as a likely viable commercial product that's underpriced here. If anything, the case matters mainly as an overhang. An uncertain $0-to-$1B+ claim is hard for any acquirer or partner to price, so resolution in almost any direction clears the path for corporate action.
The distraction is creating the opportunity.
Disclosure: Creek Drive and its affiliated funds holds a long position in NKTR. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.
Teldar Paper retweeted
$NKTR v $lly
No verdict today. Getting closer to AA data which might be a good thing. Anyways, Jury back tomorrow.
They’re now into their 4th day. And shame the stocks given up nearly $200m in mc on a simple question jury asked. Just goes to show how broken mechanics are right now across the board. A jury that settled on $1 nominal after Tue's note would have been done by now. More likely they're working through liability and the damages number, which needs to be unanimous.
Nothing to do but wait.

























